MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ombrabulin hydrochloride

CAS No. : 253426-24-3

MCE 站：Ombrabulin hydrochloride

产品活性：Ombrabulin hydrochloride 是 CA-4 磷酸酯的衍生物，选择性破坏内皮细胞的微管蛋白细胞骨架，具有抗血管作用。

研究领域：Cell Cycle/DNA Damage  |  Cytoskeleton

作用靶点：Microtubule/Tubulin

In Vitro: The effect of Ombrabulin (AVE8062) on endothelial or tumor cell viability is examined using the MTT assay. The IC₅₀ of Ombrabulin for the mouse mesenteric endothelial cells (MMEC) is 10 nM and ranges between 7 and 20 nM for the tumor cell lines (HeyA8, SKOV3ip1, and HeyA8-MDR). Comparative analysis of the nonlinear least-squares regression of the dose-response curves for each agent alone and combination Ombrabulin /Docetaxel show a significantly lower IC₅₀ than either agent alone (P<0.005, all cell lines). The cytotoxicity of Docetaxel is 2- to 4-fold greater in combination with Ombrabulin for the endothelial and tumor cells compared with Docetaxel alone.

In Vivo: Before performing therapy experiments, the tolerability of various doses of Ombrabulin (AVE8062) ranging from 10 to 100 mg/kg is tested given twice weekly via i.v., i.p., or s.c. routes in nude mice (n=3 per group). The i.v. and s.c. routes are not pursued further due to problems with skin or tail vein necrosis. The i.p. route is well tolerated with doses up to 100 mg/kg. Next, preliminary experiments are done to determine the lowest dose for in vivo therapeutic efficacy. Starting 7 days after tumor cell injection, nude mice (n=5 per group) bearing HeyA8 ovarian cancer cells are treated with either vehicle or Ombrabulin 10, 30, 50, and 100 mg/kg twice weekly i.p. for 3 weeks. There is 65% reduction in tumor weight in the 30 mg/kg group compared with the vehicle control group (P<0.02). The 10 mg/kg dose is not effective. The antitumor effects at doses >30 mg/kg are not significantly better; therefore, the 30 mg/kg dose is selected for subsequent therapy experiments.

相关产品：Natural Product Like Compound Library  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Anti-COVID-19 Compound Library  |  Cytoskeleton Compound Library  |  Paclitaxel  |  Docetaxel  |  Nocodazole  |  Vincristine sulfate  |  Colchicine  |  VcMMAE  |  Mertansine  |  Eribulin mesylate  |  Vinorelbine ditartrate  |  2-Methoxyestradiol  |  Vinblastine sulfate  |  D8-MMAE  |  DM4  |  Cabazitaxel  |  McMMAF  |  Epothilone D  |  MMAF hydrochloride  |  Taltobulin  |  Flubendazole  |  Epothilone B  |  Estramustine phosphate sodium  |  Parbendazole  |  Triclabendazole  |  Combretastatin A4  |  Fosbretabulin disodium  |  Ixabepilone  |  Ansamitocin P-3  |  Podofilox  |  BTB-1

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。